An update on intravitreal implants in use for eye disorders

Area of Science:

• Ophthalmology
• Biotechnology
• Pharmacology

Background:

• Intravitreal drug delivery systems have advanced significantly using new biotechnologies and polymers.
• Corticosteroids are essential for treating uveitis and macular edema.
• There is a need for sustained drug delivery with reduced systemic side effects.

Purpose of the Study:

• To review innovative intravitreal corticosteroid implants for managing ocular inflammatory and edematous conditions.
• To discuss the advantages and potential side effects of currently available long-acting corticosteroid implants.

Main Methods:

• Review of commercially available long-acting corticosteroid implants: Retisert®, Iluvien®, and Ozurdex®.
• Comparison of these implants with traditional steroid injections and anti-VEGF therapies like ranibizumab.

Main Results:

• Three long-acting corticosteroid implants are available for conditions including uveitis, macular edema, retinal vein occlusion, diabetes, and pseudophakia.
• These implants provide long-term control of inflammation and edema with less frequent administration compared to injections.
• Potential side effects include cataract formation and glaucoma, necessitating careful patient selection and monitoring.

Conclusions:

• Long-acting intravitreal corticosteroid implants represent a significant advancement in managing chronic ocular conditions.
• Further research is needed to establish the relative efficacy and optimal indications for each implant.
• Continued development of novel drug delivery devices is essential for improving patient outcomes.